➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts
Merck
AstraZeneca
McKinsey

Last Updated: April 12, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Arbaclofen Placarbil

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Arbaclofen Placarbil?

Arbaclofen Placarbil is an investigational drug.

There have been 7 clinical trials for Arbaclofen Placarbil. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2011.

The most common disease conditions in clinical trials are Gastroesophageal Reflux, Back Pain, and Disease. The leading clinical trial sponsors are Indivior Inc. and [disabled in preview].

There are sixty-two US patents protecting this investigational drug and six hundred and seventy-eight international patents.

Recent Clinical Trials for Arbaclofen Placarbil
TitleSponsorPhase
A Phase 1 Bioavailability Study of Arbaclofen Placarbil Modified Release Formulations in Healthy VolunteersIndivior Inc.Phase 1
A Dose-Escalation Study to Determine the Maximum Tolerated Dose of Arbaclofen Placarbil in Subjects With Alcohol Use DisorderIndivior Inc.Phase 2
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple SclerosisIndivior Inc.Phase 3

See all Arbaclofen Placarbil clinical trials

Clinical Trial Summary for Arbaclofen Placarbil

Top disease conditions for Arbaclofen Placarbil
Top clinical trial sponsors for Arbaclofen Placarbil

See all Arbaclofen Placarbil clinical trials

US Patents for Arbaclofen Placarbil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Arbaclofen Placarbil   Start Trial Therapeutic approaches for treating Parkinson's disease Pharnext (Issy les Moulineaux, FR)   Start Trial
Arbaclofen Placarbil   Start Trial Therapeutic approaches for treating Parkinson's disease PHARNEXT (Issy les Moulineaux, FR)   Start Trial
Arbaclofen Placarbil   Start Trial Compositions for treating amyotrophic lateral sclerosis PHARNEXT (Issy les Moulineaux, FR)   Start Trial
Arbaclofen Placarbil   Start Trial Sustained release oral dosage forms of an R-baclofen prodrug XENOPORT, INC. (Santa Clara, CA)   Start Trial
Arbaclofen Placarbil   Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Arbaclofen Placarbil

Drugname Country Document Number Estimated Expiration Related US Patent
Arbaclofen Placarbil Australia AU2012222348 2031-03-01   Start Trial
Arbaclofen Placarbil Australia AU2012222351 2031-03-01   Start Trial
Arbaclofen Placarbil Australia AU2013224959 2031-03-01   Start Trial
Arbaclofen Placarbil Australia AU2013224960 2031-03-01   Start Trial
Arbaclofen Placarbil Australia AU2014314055 2031-03-01   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
Express Scripts
Merck
AstraZeneca
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.